HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
abemaciclib Sensitive: A1 - Approval
Precision Oncology News - 1 week (New A1)
|
abemaciclib Sensitive: A1 - Approval
Precision Oncology News - 1 week - (New A2)
|
BRCA2 mutation + HR positive
|
HER2 Negative Breast Cancer
|
BRCA2 mutation + HR positive
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
Medicine (Baltimore) - 2 weeks (New A2)
|
olaparib Sensitive: A2 - Guideline
Medicine (Baltimore) - 2 weeks - (New C4)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A1 - Approval
Mol Clin Oncol - 3 weeks (New A1)
|
palbociclib Sensitive: A1 - Approval
Mol Clin Oncol - 3 weeks - (New C3)
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
AZD5363 Sensitive: C3 – Early Trials
Lancet Oncol - 3 weeks (New C3)
|
AZD5363 Sensitive: C3 – Early Trials
Lancet Oncol - 3 weeks - (New C3)
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A1 - Approval
|
ribociclib Sensitive: A1 - Approval
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A1 - Approval
|
alpelisib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
everolimus Sensitive: A1 - Approval
|
everolimus Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A1 - Approval
|
talazoparib Sensitive: A1 - Approval
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
fulvestrant Sensitive: A1 - Approval
|
fulvestrant Sensitive: A1 - Approval
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
CaT Sensitive: A2 - Guideline
|
CaT Sensitive: A2 - Guideline
|
HR negative + BRCA1 mutation
|
HER2 Negative Breast Cancer
|
HR negative + BRCA1 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
PARP inhibitor Sensitive: A2 - Guideline
|
PARP inhibitor Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: A2 - Guideline
|
ribociclib Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
docetaxel Sensitive: A2 - Guideline
|
docetaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
albumin-bound paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
ixabepilone Sensitive: A2 - Guideline
|
ixabepilone Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
gemcitabine Sensitive: A2 - Guideline
|
gemcitabine Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
vinorelbine tartrate Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
toremifene Sensitive: A2 - Guideline
|
toremifene Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
anastrozole Sensitive: A2 - Guideline
|
anastrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
carboplatin + docetaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
tamoxifen Sensitive: A2 - Guideline
|
tamoxifen Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
everolimus Sensitive: A2 - Guideline
|
everolimus Sensitive: A2 - Guideline
|
HR negative + BRCA2 mutation
|
HER2 Negative Breast Cancer
|
HR negative + BRCA2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
TC Sensitive: A2 - Guideline
|
TC Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
fulvestrant Sensitive: A2 - Guideline
|
fulvestrant Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
fulvestrant + anastrozole Sensitive: A2 - Guideline
|
fulvestrant + anastrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
fulvestrant + letrozole Sensitive: A2 - Guideline
|
fulvestrant + letrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: A2 - Guideline
|
palbociclib Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
abemaciclib Sensitive: A2 - Guideline
|
abemaciclib Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
exemestane Sensitive: A2 - Guideline
|
exemestane Sensitive: A2 - Guideline
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
talazoparib Sensitive: A2 - Guideline
|
talazoparib Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
Aromatase inhibitor Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
carboplatin + paclitaxel Sensitive: A2 - Guideline
|
ER positive + PGR positive
|
HER2 Negative Breast Cancer
|
ER positive + PGR positive
|
HER2 Negative Breast Cancer
|
anastrozole Sensitive: A2 - Guideline
|
anastrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
EC Sensitive: A2 - Guideline
|
EC Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
CMF Sensitive: A2 - Guideline
|
CMF Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
paclitaxel Sensitive: A2 - Guideline
|
paclitaxel Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
AC Sensitive: A2 - Guideline
|
AC Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
TAC Sensitive: A2 - Guideline
|
TAC Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
fulvestrant Sensitive: A2 - Guideline
|
fulvestrant Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
GT Sensitive: A2 - Guideline
|
GT Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
epirubicin Sensitive: A2 - Guideline
|
epirubicin Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
cyclophosphamide Sensitive: A2 - Guideline
|
cyclophosphamide Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline
|
lyso-thermosensitive liposomal doxorubicin Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
doxorubicin hydrochloride Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
estradiol Sensitive: A2 - Guideline
|
estradiol Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
megestrol Sensitive: A2 - Guideline
|
megestrol Sensitive: A2 - Guideline
|
HR negative + PD-L1 expression
|
HER2 Negative Breast Cancer
|
HR negative + PD-L1 expression
|
HER2 Negative Breast Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
HR negative + PD-L1 expression
|
HER2 Negative Breast Cancer
|
HR negative + PD-L1 expression
|
HER2 Negative Breast Cancer
|
atezolizumab Sensitive: A2 - Guideline
|
atezolizumab Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
carboplatin Sensitive: A2 - Guideline
|
carboplatin Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
eribulin mesylate Sensitive: A2 - Guideline
|
eribulin mesylate Sensitive: A2 - Guideline
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
CDK6 inhibitor Sensitive: A2 - Guideline
|
CDK6 inhibitor Sensitive: A2 - Guideline
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor Sensitive: A2 - Guideline
|
CDK4 inhibitor Sensitive: A2 - Guideline
|
PGR positive
|
HER2 Negative Breast Cancer
|
PGR positive
|
HER2 Negative Breast Cancer
|
anastrozole Sensitive: A2 - Guideline
|
anastrozole Sensitive: A2 - Guideline
|
PGR positive
|
HER2 Negative Breast Cancer
|
PGR positive
|
HER2 Negative Breast Cancer
|
letrozole Sensitive: A2 - Guideline
|
letrozole Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
exemestane Sensitive: A2 - Guideline
|
exemestane Sensitive: A2 - Guideline
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline
|
CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + HR positive
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline
|
CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline
|
BRCA1 mutation + HR positive
|
HER2 Negative Breast Cancer
|
BRCA1 mutation + HR positive
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
capecitabine Sensitive: A2 - Guideline
|
capecitabine Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
bevacizumab Sensitive: A2 - Guideline
|
bevacizumab Sensitive: A2 - Guideline
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
vinorelbine Sensitive: A2 - Guideline
|
vinorelbine Sensitive: A2 - Guideline
|
PIK3CA exon 20 mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA exon 20 mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A2 - Guideline
|
alpelisib Sensitive: A2 - Guideline
|
PIK3CA exon 7 mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA exon 7 mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A2 - Guideline
|
alpelisib Sensitive: A2 - Guideline
|
PIK3CA exon 9 mutation + HR positive
|
HER2 Negative Breast Cancer
|
PIK3CA exon 9 mutation + HR positive
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: A2 - Guideline
|
alpelisib Sensitive: A2 - Guideline
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
PALB2 mutation
|
HER2 Negative Breast Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
HR negative
|
HER2 Negative Breast Cancer
|
HR negative
|
HER2 Negative Breast Cancer
|
pembrolizumab Sensitive: A2 - Guideline
|
pembrolizumab Sensitive: A2 - Guideline
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
HER-2 negative
|
HER2 Negative Breast Cancer
|
POL 6326 Sensitive: B - Late Trials
|
POL 6326 Sensitive: B - Late Trials
|
PIK3CA mutation + ER positive
|
HER2 Negative Breast Cancer
|
PIK3CA mutation + ER positive
|
HER2 Negative Breast Cancer
|
GDC-0032 Sensitive: B - Late Trials
|
GDC-0032 Sensitive: B - Late Trials
|
PIK3CA mutation
|
HER2 Negative Breast Cancer
|
PIK3CA mutation
|
HER2 Negative Breast Cancer
|
alpelisib Sensitive: B - Late Trials
|
alpelisib Sensitive: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
sacituzumab govitecan-hziy Sensitive: B - Late Trials
|
sacituzumab govitecan-hziy Sensitive: B - Late Trials
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
gimeracil/oteracil/tegafur Sensitive: B - Late Trials
|
gimeracil / oteracil / tegafur Sensitive: B - Late Trials
|
ER positive
|
HER2 Negative Breast Cancer
|
ER positive
|
HER2 Negative Breast Cancer
|
palbociclib Sensitive: B - Late Trials
|
palbociclib Sensitive: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
PI3K inhibitor Sensitive: B - Late Trials
|
PI3K inhibitor Sensitive: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
DJ 927 Sensitive: B - Late Trials
|
DJ 927 Sensitive: B - Late Trials
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
BRCA2 mutation
|
HER2 Negative Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
BRCA1 mutation
|
HER2 Negative Breast Cancer
|
ABT-888 Sensitive: B - Late Trials
|
ABT-888 Sensitive: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
albumin-bound paclitaxel Sensitive: B - Late Trials
|
albumin-bound paclitaxel Sensitive: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
SNDX-275 Resistant: B - Late Trials
|
SNDX-275 Resistant: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
capecitabine + DJ 927 Sensitive: B - Late Trials
|
capecitabine + DJ 927 Sensitive: B - Late Trials
|
ER positive + PGR negative + HER-2 negative
|
HER2 Negative Breast Cancer
|
ER positive + PGR negative + HER-2 negative
|
HER2 Negative Breast Cancer
|
ribociclib Sensitive: B - Late Trials
|
ribociclib Sensitive: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
CDK6 inhibitor Sensitive: B - Late Trials
|
CDK6 inhibitor Sensitive: B - Late Trials
|
HR positive
|
HER2 Negative Breast Cancer
|
HR positive
|
HER2 Negative Breast Cancer
|
CDK4 inhibitor Sensitive: B - Late Trials
|
CDK4 inhibitor Sensitive: B - Late Trials
|